Home
Search

Press Releases

Get the latest on BIO’s announcements, positions, and views.

Featured Press Releases
BIO Statement on the FDA’s ‘Fit-for-Purpose Rare…
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement on the FDA’s ‘Fit-for-Purpose Rare Disease Framework Initiative.’“Today’s announcement is an important step…
Learn more
BIO Statement on Finalization of the Globe Model
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement on the finalization of the GLOBE model.“Biotechnology is one of America's greatest strengths, delivering…
Learn more
Nevada Governor Joe Lombardo Named BIO’s Governor…
WASHINGTON, DC (August 31, 2026) – Today, the Biotechnology Innovation Organization (BIO) awarded Nevada Governor Joe Lombardo with its 2026 Governor of the Year Award, recognizing his leadership in growing the life sciences in Nevada and commitment…
Learn more
All Press Releases
  • Show All
Search
Event Tags
BIO Statement on the FDA’s ‘Fit-for-Purpose Rare Disease Framework Initiative.’
October 14, 2026
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement on the FDA’s ‘Fit-for-Purpose Rare Disease Framework Initiative.’“Today’s announcement is an important step…
BIO Statement on Finalization of the Globe Model
September 30, 2026
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement on the finalization of the GLOBE model.“Biotechnology is one of America's greatest strengths, delivering…
Nevada Governor Joe Lombardo Named BIO’s Governor of the Year
August 31, 2026
WASHINGTON, DC (August 31, 2026) – Today, the Biotechnology Innovation Organization (BIO) awarded Nevada Governor Joe Lombardo with its 2026 Governor of the Year Award, recognizing his leadership in growing the life sciences in Nevada and commitment…
BIO Supports PDUFA VIII Commitment Letter and Urges Timely Reauthorization
August 13, 2026
Biotechnology Innovation Organization (BIO) Senior Vice President of Science & Regulatory Affairs Annetta Beauregard issued the following statement on the release of the Prescription Drug User Fee Act (PDUFA) VIII commitment letter:“For more…
BIO Statement on Senate Reintroduction of the PASTEUR Act
June 24, 2026
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement on the reintroduction of the bipartisan Pioneering Antimicrobial Subscriptions to End Upsurging Resistance …
BIO International Convention Returns to San Diego to Celebrate Five Decades of Biotechnology
June 22, 2026
20,000+ biotech leaders gather with a shared mission: to improve lives  SAN DIEGO (June 22, 2026) - The BIO International Convention (BIO 2026), the world’s largest and most comprehensive event for the biotechnology industry, begins today…
BIO Statement on Veto of Prescription Drug Affordability Boards (PDAB) in Virginia
May 22, 2026
Patrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB)…
BIO Statement on Resignation of FDA Commissioner Marty Makary
May 12, 2026
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement on the resignation of FDA Commissioner Marty Makary.“Dr. Makary inherited an FDA in crisis after the DOGE…
BIO Launches “The Fight of Our Lives,” a National Campaign to Spotlight the Impact of Biotechnology on the Lives of Patients and Families​​ ​
April 15, 2026
WASHINGTON, DC – Today, the Biotechnology Innovation Organization (BIO) announced the launch of ​​The Fight of Our Lives, a new national campaign focused on the stories behind biotechnology breakthroughs, the patients whose lives depend on them…
BIO Statement on the Section 232 Pharmaceutical Proclamation
April 2, 2026
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement on Section 232 Pharmaceutical Proclamation.“A thriving American biotechnology ecosystem is essential to…